|Professor||Akira WATANABE, MD|
|Visiting Professor||Shigeru FUJIMURA|
|Technical Assistant||Tomoko ITO|
|Technical Assistant||Tomomi NAKANO|
The Division of Anti-Effective Agents was established to actively and voluntarily undertake the development of not only antibiotics and antimicrobials, but antifungals, tuberculostatics, antivirals, and various vaccines. We have experienced the advent of emerging infections such as AIDS and the resurgence of reemerging infections such as intractable tuberculosis in the 1980s, and even the spread of MRSA and multidrug-resistant Streptococcus pneumoniae in the 1990s. In the 2000s, the increase in fatalities from AIDS and the emergence of drug-resistant bacteria such as multidrug-resistant Pseudomonas aeruginosa and super-resistant strain of Mycobacterium tuberculosis have attracted social attention. As for infections and resistant bacteria, it is not only necessary to stop the spread of outbreak, but to also control the outbreak itself. We intend to accomplish this by placing more emphasis on the prevention of possible outbreaks, rather than the containment of infectious and resistant bacteria.
•Leading-edge drug discovery and development in medical and pharmaceutical sciences, promotion of researches on pharmaceutical agent, and development of human resources.
•Promotion of clinical studies on novel anti-infectives, improvement of post-marketing clinical studies, and promotion of international standardization.
•Establishment of proper usage of anti-infectives based on drug characteristics and promotion of clinical researches.
•Prevention of in-hospital infection, promotion of researches on drug-resistant bacteria control, and dissemination and promotion of achievements.
•Promotion of researches on zoonotic infections and anti-bioterrorism measures.
•Promotion of development and practical application of bird flu anti-viral drugs.
•Basic and clinical researches on drug-resistant bacteria and promotion of its control.
•Epidemiological measures for the prevention of chronic infections such as tuberculosis and the promotion of prospective treatment and prevention.